reimbursement

Assessing the impact of prevalence on pricing of rare disease drugs in Germany

  • by

In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in reimbursement decisions among payers in Germany. Historically, payers have accepted factors including small target patient populations and high clinical development… Read More »Assessing the impact of prevalence on pricing of rare disease drugs in Germany

46 hospitals file suit to reverse HHS bad debt policy

  • by

A group of hospitals have sued HHS Secretary Alex Azar, arguing he should reverse a policy that prevents hospitals from getting reimbursed for Medicare-related bad debts pending at outside collection agencies. The policy has raised hospital debt payments by about $1.35 million, the lawsuit claims.